UK cancer drug companies combine expertise in merger

UK oncology company Incanthera says it has acquired Onco-NX, the University of Salford drug discovery spin-out in 2011. Financial terms of the transaction were not disclosed.

The deal represents the first successful sale of a spin-out company from the university and will see both companies combine their expertise in targeted anticancer drugs, to develop a ground-breaking, therapeutics pipeline.

Manchester-based Incanthera has developed a 'smart bomb' therapy which selectively targets solid tumors without harming healthy cells. This means there is the potential of virtually no side effects to the rest of the body.